



TCR/ITK Signaling in Type 1 Regulatory T cells

7

Michael C. McGee, Avery August, and Weishan Huang

Abstract

Type 1 regulatory T (Tr1) cells can modulate inflammation through multiple direct and indirect molecular and cellular mechanisms and have demonstrated potential for anti-inflammatory therapies. Tr1 cells do not express the master transcription factor of conventional regulatory T cells, Foxp3, but express high levels of the immunomodulatory cytokine, IL-10. IL-2-inducible T-cell kinase (ITK) is conserved between mouse and human and is highly expressed in T cells. ITK signaling downstream of the T-cell receptor (TCR) is critical for T-cell subset differentiation and function. Upon activation by TCR, ITK is critical for Ras activation, leading to downstream activation of MAPKs and upregulation

of IRF4, which further enable Tr1 cell differentiation and suppressive function. We summarize here the structure, signaling pathway, and function of ITK in T-cell lineage designation, with an emphasis on Tr1 cell development and function.

Keywords

ITK · TCR · Tr1 cells · Ras · IRF4

7.1 Introduction

Regulatory T cells are critical in promoting self-tolerance and preventing immunopathology from excessive inflammation. Transcription factor Foxp3 is a well-recognized lineage specification factor of conventional T regulatory (Treg) cells. Foxp3⁺ conventional Treg cells express Foxp3 and CD25 as identifying markers and are important immune regulators that promote self-tolerance and immune homeostasis in human and mouse (Bennett et al. 2001; Brunkow et al. 2001; Chatila et al. 2000; Fontenot et al. 2003; Gambineri et al. 2003; Hori et al. 2003; Khattri et al. 2003; Sakaguchi et al. 1995; Shevach et al. 2001; Wildin et al. 2001). Type 1 regulatory T (Tr1) cells, on the other hand, lack the expression of Foxp3 and CD25, but express high levels of the immunomodulatory cytokine IL-10, which can suppress inflammatory responses associated with type 2 cytokines (IL-4/5/13) and IL-17 responses

M. C. McGee
Department of Pathobiological Sciences, School of
Veterinary Medicine, Louisiana State University, Baton
Rouge, LA, USA

A. August
Department of Microbiology and Immunology, College of
Veterinary Medicine, Cornell University, Ithaca, NY,
USA

W. Huang (✉)
Department of Pathobiological Sciences, School of
Veterinary Medicine, Louisiana State University, Baton
Rouge, LA, USA

Department of Microbiology and Immunology, College of
Veterinary Medicine, Cornell University, Ithaca, NY,
USA
e-mail: huang1@lsu.edu

(Gagliani et al. 2013; Gol-Ara et al. 2012; Huber et al. 2011; Okamura et al. 2012). Tr1 cells directly suppress the effector cell response through the secretion of IL-10, granzyme-dependent killing of antigen-presenting cells, and expression of coinhibitory receptors such as CTLA-4 and PD-1 (Akdis 2008; Haringer et al. 2009; Huber et al. 2011; Magnani et al. 2011). Indirect immune suppression by Tr1 cells has been shown as well, such as depletion of proinflammatory extracellular ATP by CD39 expressed on Tr1 cells (Mascanfroni et al. 2015).

Tr1 cells have been shown to suppress the development of diseases such as allergic asthma, colitis, and atopic dermatitis in animal models (Ahangerani et al. 2009; Groux et al. 1997; Volz et al. 2014). Antigen-specific tolerance correlates positively with Tr1 numbers during hematopoietic stem cell transplant and immunotherapy (Bohm et al. 2015; Serafini et al. 2009). Their ability to regulate inflammation and induce tolerance makes Tr1 cells a promising candidate for immunotherapies (Bohm et al. 1998; Gol-Ara et al. 2012; Mobs et al. 2010; Roncarolo et al. 2014; Volz et al. 2014; Zeng et al. 2015). However, this potent regulatory activity has the potential to “cut both ways” by hindering the protective response toward pathogens or tumors. Patients with chronic hepatitis C possess higher numbers of virus-specific Tr1 cells than patients who spontaneously clear the infection (Brady et al. 2003; MacDonald et al. 2002). In a mouse model of *Bordetella pertussis*, pathogen-specific Tr1 cells have been shown to suppress the protective Th1 response (McGuirk et al. 2002). Tr1 cells isolated from tumors display immunosuppressive functions *ex vivo* (Bergmann et al. 2008; Pedroza-Gonzalez et al. 2015). Thus, understanding the signaling pathways that drive Tr1 differentiation and function is of great interest. While much is known about signaling pathways involved in Treg cell development and function (Sakaguchi et al. 2008; Vignali et al. 2008), significantly less is known about the molecular mechanisms regulating Tr1 cell development and how they function against inflammation.

Members of the Tec family of nonreceptor tyrosine kinases are critical in signaling pathways

of the immune system (August and Ragin 2012; Berg et al. 2005; Gilfillan and Rivera 2009). IL-2-inducible T-cell kinase (ITK) is the predominant Tec family kinase expressed in T cells and is a signaling mediator downstream of the T-cell receptor (TCR) (August et al. 2002). ITK plays major roles in modulating T-cell development, activation, differentiation, and function (Gomez-Rodriguez et al. 2014, 2016; Huang et al. 2014; Kannan et al. 2015; Schaeffer et al. 2000, 2001). The role of ITK in the differentiation and function of several T helper (Th) lineages is well studied (August and Ragin 2012; Gomez-Rodriguez et al. 2014; Huang et al. 2014; Kannan et al. 2013; Miller et al. 2004). However, it has only been recently explored in Tr1 cells (Huang et al. 2017). This chapter summarizes the role of ITK in TCR signaling and Th cell differentiation, with an emphasis on the role of ITK in Tr1 cell differentiation and function.

7.2 Structure of ITK

ITK is a member of the Tec family kinases and is expressed by mast cells and T cells, with a predominant preference in T cells (Andreotti et al. 2010; August et al. 2002). Tec family includes ITK, BTK, TEC, BMX, and TXK and is the second largest non-receptor protein-tyrosine kinase family (second to Src family) (Takesono et al. 2002). These kinases are classified based on the unique Tec-Homology (TH) domain, which is composed of a zinc-binding Btk-homology (BH) motif and/or proline-rich regions (PRR). ITK and its family members share a high homology in structure consisting of, from protein N terminal to C terminal, pleckstrin homology (PH), TH (BH + PRR), Src-homology (SH) 3, SH2, and kinase domains (Fig. 7.1a) (Felices et al. 2007). At the steady state in resting T cells, ITK normally resides in the cytosolic compartment, and the PH domain is critical in recruiting ITK to the plasma membrane upon TCR activation (August et al. 1997). The SH3 and SH2 domains are important for mediating protein–protein interactions between ITK and other components of the TCR signaling complex,




Fig. 7.1 Structure of ITK. (a) Schematic of structure of ITK: from N to C terminus, there are PH, TH, SH3, SH3, and kinase domains. (b) Structures of kinase domain of WT and allele sensitive (*as*) mutant of ITK (upper panel). ITK_{as} harbors an F435G mutant (black and green arrows)

in the ATP binding pocket (lower panel) of ITK kinase domain along with a Δ A429 (red arrows) to preserve the ITK kinase activity of ITK_{as}. (Modified from the authors' previous publication (Kannan et al. 2015))

most notably SLP-76 (Berg et al. 2005; Bunnell et al. 2000; Su et al. 1999). In addition, these SH2 and SH3 protein–protein interactions are critical for kinase-independent functions in regulating actin cytoskeleton rearrangement (Dombroski et al. 2005; Grasis et al. 2003).

The C-terminal kinase domain has high levels of structural similarity between ITK and other Tec family members, making it challenging to identify small molecule inhibitors that would be specific for ITK over the other Tec kinases. The presence of unique gatekeeper residues in the kinase domain may enable the development of an allele-sensitive kinase domain that allows temporal inhibition of the kinase activity using small molecule inhibitors (Bishop et al. 1998). A bulky gatekeeper residue, F435, has been identified in ITK, and substitution of this residue with the short chain glycine (F435G) allows for bulkier ATP analogs to efficiently compete for the ATP binding and prevent activation of this allele sensitive mutant of ITK (ITK_{as}) (Fig. 7.1b) (Shokat and Velleca 2002). These bulkier ATP analogs include modified derivatives of the Src-kinase inhibitor PP1 (1-(1,1-dimethylethyl)-3-(4-methylphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine) such as 3MB-PP1

(1-(1,1-dimethylethyl)-3-[(3-methylphenyl)methyl]-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine), 1NM-PP1 (1-(1,1-dimethylethyl)-3-(1-naphthalenylmethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine), and 1-NA-PP1 (1-(1,1-dimethylethyl)-3-(1-naphthalenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine), that have unique selectivity for kinases that are modified by substitution of similarly located gatekeeper residues in other kinases (Bishop et al. 2000).

7.3 TCR/ITK Signaling Pathway

The TCR is stimulated upon interaction with the peptide/MHC complex on antigen-presenting cells. This interaction results in the phosphorylation of Lck. Lck phosphorylates the ITAMs on the cytoplasmic CD3 ζ chain which allows for recruitment and phosphorylation of ZAP-70. Activated ZAP-70 phosphorylates the adaptor proteins LAT and SLP-76 which forms a crucial scaffold for the TCR signaling complex or signalosome (Werlen and Palmer 2002). Lck also phosphorylates phosphatidylinositol 3-kinase (PI3K) which generates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) lipids in

the plasma membrane. ITK is recruited to the plasma membrane by PIP3 via the PH domain (August et al. 1997) where it is phosphorylated by Lck. This event allows ITK to interact with the TCR signalosome via phosphorylated tyrosine 145 on SLP-76 via its SH2 domain (Su et al. 1999). Once associated with the signalosome, ITK activates PLC γ -1 via phosphorylation. Activated PLC γ -1 converts membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG) (Schaeffer et al. 1999). IP3 stimulates IP3R on the endoplasmic reticulum (ER), resulting in release of STIM1-mediated ER calcium (Ca²⁺) stores into the cytoplasm. Depletion of ER Ca²⁺ stores results in an influx of extracellular Ca²⁺ through calcium release-activated channels such as Orai1 on the plasma membrane (Smith-Garvin et al. 2009). Increased intracellular Ca²⁺ levels activate calcineurin which dephosphorylates and promotes nuclear translocation of NFAT (Smith-Garvin et al. 2009). Production of DAG leads to the activation of Ras/Raf1/MAPK pathway (Smith-Garvin et al. 2009), which can further lead to activation and upregulation of transcription factor AP-1 and IRF family members (Huang et al. 2017; Schaeffer et al. 2001). DAG also recruits PKC θ to the plasma membrane where it regulates NF- κ B activation and nuclear translocation (Smith-Garvin et al. 2009). This TCR/ITK signaling pathway is detailed in Fig. 7.2.

TCR signaling still occurs in the absence of ITK, but with attenuated strength (August and Ragin 2012; Schaeffer et al. 2001), which makes ITK more a signal amplifier rather than a signal switch during T-cell activation (August and Ragin 2012). In the absence of ITK, activation of the MAPK pathway and downstream AP-1 and IRF4 transcription factors is reduced, as well as the calcium flux and NFAT activity (Huang et al. 2017; Schaeffer et al. 2001); NF- κ B activation is also impaired, but to a lesser extent than MAPK and NFAT pathways (Fowell et al. 1999; Schaeffer et al. 2001). The attenuation of these signaling pathways has consequences for T-cell subset differentiation and function.

7.4 Kinase-Independent ITK Function

ITK also has kinase-independent functions during TCR activation. Upon T-cell activation, ITK directly interacts with Vav, a regulator of actin polymerization, via the SH2 domain (Dombroski et al. 2005). In mouse models of *Itk* deficiency, T-cell-specific expression of ITK with mutations in the SH2 and SH3 domain display impaired actin polymerization along with reduced recruitment of Vav to the signaling complex during T-cell activation (Dombroski et al. 2005; Grasis et al. 2003). However, ITK kinase dead mutants do not show this deficiency, suggesting that ITK acts as part of a scaffold important for cytoskeleton reorganization independently of its kinase activity (Fig. 7.2) (Dombroski et al. 2005; Grasis et al. 2003; Hao et al. 2006; Qi et al. 2011; Sahu et al. 2008).

7.5 Function of ITK in T Helper Cell Designation

The role of ITK in T-cell subset differentiation and function has been well studied over the past two decades (Fig. 7.3). Naïve CD4 cells preferentially differentiate into IFN- γ -producing Th1 cells in the absence of ITK, partly due to its negative regulation of Tbet expression (Kannan et al. 2013; Miller et al. 2004). *Itk*-deficient mice have defects in Th2 differentiation and function and were reported to be resistant to developing allergic airway inflammation (Au-Yeung et al. 2006; Fowell et al. 1999; Kannan et al. 2013). ITK plays a crucial role in regulating the balance between Th17 and Treg cell differentiation in part via regulating sensitivity to IL-2 (Gomez-Rodriguez et al. 2014). Under Th17-polarizing conditions, ITK signals suppress Treg cell differentiation while promoting Th17 differentiation (Gomez-Rodriguez et al. 2014; Huang et al. 2014). Importantly, impaired calcium/NFAT signaling in *Itk*^{-/-} CD4⁺ cells results in decreased cytokine production by both Th17 and Th2 cells (Fowell et al. 1999; Gomez-Rodriguez et al. 2009). ITK has also been shown to be critical in Th9




Fig. 7.2 Scheme of TCR signaling through ITK. (Modified from the authors' previous publication (Kannan et al. 2012))




Fig. 7.3 ITK function in Th and regulatory T-cell differentiation and function. Note that ITK signals through Ras/MAPK/IRF4 are critical for Tr1 cell development and suppressive function

differentiation by regulating induction of IL-2/STAT5 signaling leading to upregulation of IRF4 (Gomez-Rodriguez et al. 2016). The roles of ITK in regulating cytokine production in Th1, Th2, and Th17 cells are dependent on the kinase activity of ITK (Kannan et al. 2015).

7.6 TCR/ITK → Ras/MAPK/IRF4 Pathway in Tr1 Cells

Naïve CD4⁺ cells can differentiate into Tr1 cells upon TCR stimulation in the presence of IL-27 (Fitzgerald et al. 2007). Th17 cells are also capable of transdifferentiating into Tr1 cells upon resolution of inflammation (Gagliani et al. 2015). IL-27 signals through STAT1 and STAT3 to induce a network of transcription factors, including IRF4, Blimp-1, Ahr, and c-Maf, that controls Tr1 differentiation (Apetoh et al. 2010; Cretney et al. 2011; Pot et al. 2011; Stumhofer et al. 2007). The absence of ITK or ITK kinase activity results in severely impaired upregulation of IL-10, Tr1 cell associated surface markers, and transcription factors under Tr1 cell-inducing conditions both in vivo and in vitro. Indeed, anti-CD3 antibody treatment induces significantly less Tr1 cells in *Itk*^{-/-} compared to WT mice. The absence of ITK also reduced the development of Tr1 cells in models of parasitic and viral infections. Inhibition of ITK kinase activity significantly reduced Th17 to Tr1 cell trans differentiation in vitro. Furthermore, ITK kinase activity is critical for upregulating the expression of transcription factors IRF4, Ahr, and Blimp-1, all of which are involved in regulating Tr1 cell development, in both mouse and human (e.g., Maf appears to be downstream of ITK in mice, but not human Tr1 cell differentiation). Downstream of TCR/ITK, Ras/MAPK pathway is upregulated, further leading to upregulation of IRF4 expression. Using *ITKas*-expressing Tr1 cells co-cultured with TCR-activated WT responder T cells, *ITKas* kinase activity was shown to be critical in the suppressive function of Tr1 cells against responder T-cell expansion. This reduction in

suppression coincided with a decrease in IL-10 production. Importantly, *Itk*^{-/-} Tr1 cell differentiation could be rescued when IRF4 was reintroduced via retroviral transduction, and the resultant IRF4-expressing *Itk*^{-/-} Tr1 cells were functionally suppressive. Taken together, these data show that the TCR/ITK → Ras/MAPK/IRF4 signaling pathway is critical in both Tr1 differentiation and suppressive function (Fig. 7.3) (Huang et al. 2017).

7.7 Conclusions

Regulatory T cells serve to protect against autoimmunity and restrict immunopathology but may also prevent eradication of pathogens or tumors. While the TCR/ITK → Ras/MAPK/IRF4 pathway is crucial for Tr1 cell differentiation and function, the exact mechanism of Ras activation and signaling leading to upregulation of IRF4 has not yet been determined. Proof-of-concept clinical trials with Tr1 cells have demonstrated the safety and feasibility of this approach and indicated some preclinical benefits in graft-versus-host disease during hematopoietic stem cell transplantation (Bacchetta et al. 2014). In mouse models, IL-10-producing T cells exhibited anti-inflammatory effects in host immune rejection to organ transplants (Mfarrej et al. 2017), inflammatory bowel diseases (Clemente-Casares et al. 2016; Desreumaux et al. 2012), allergic asthma (Tousa et al. 2017), food allergy (Pellerin et al. 2018), dermatitis (Volz et al. 2014), type 1 diabetes (Clemente-Casares et al. 2016), autoimmune encephalitis (Clemente-Casares et al. 2016), arthritis (Clemente-Casares et al. 2016), acute immunopathology due to infection (Huang et al. 2017), and other related inflammatory conditions, as well as in shaping vaccine-induced immune responses (Ndure and Flanagan 2014). A more complete understanding of the signaling pathways that promote Tr1 cell differentiation and function may allow for the development of improved strategies to modulate the immune responses under different disease conditions.

Acknowledgments A.A. received research support from 3M Corporation. W.H. received research support from MegaRobo Technologies Corporation. M.C.M. declares no competing financial interests. Research related to this review topic in the authors' laboratories was supported in part by grants from the National Institutes of Health (R01AI120701, R01AI138570, R56AI146226, R21AI137822, P20GM130555-6610, R21AI129422, R21AI138497, and R35ES028244 (to Gary Perdew)). M.C.M. is a recipient of the Pathobiological Sciences Graduate Program Fellowship in the School of Veterinary Medicine at the Louisiana State University.

References

- Ahangarani RR, Janssens W, VanderElst L, Carlier V, VandenDriessche T, Chuah M, Weynand B, Vanoirbeek JA, Jacquemin M, Saint-Remy JM (2009) In vivo induction of type 1-like regulatory T cells using genetically modified B cells confers long-term IL-10-dependent antigen-specific unresponsiveness. *J Immunol* 183:8232–8243
- Akdis M (2008) T-cell tolerance to inhaled allergens: mechanisms and therapeutic approaches. *Expert Opin Biol Ther* 8:769–777
- Andreotti AH, Schwartzberg PL, Joseph RE, Berg LJ (2010) T-cell signaling regulated by the Tec family kinase, Itk. *Cold Spring Harb Perspect Biol* 2:a002287
- Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. *Nat Immunol* 11:854–861
- August A, Ragin MJ (2012) Regulation of T-cell responses and disease by tec kinase Itk. *Int Rev Immunol* 31:155–165
- August A, Sadra A, Dupont B, Hanafusa H (1997) Src-induced activation of inducible T cell kinase (ITK) requires phosphatidylinositol 3-kinase activity and the Pleckstrin homology domain of inducible T cell kinase. *Proc Natl Acad Sci U S A* 94:11227–11232
- August A, Fischer A, Hao S, Mueller C, Ragin M (2002) The Tec family of tyrosine kinases in T cells, amplifiers of T cell receptor signals. *Int J Biochem Cell Biol* 34:1184–1189
- Au-Yeung BB, Katzman SD, Fowell DJ (2006) Cutting edge: Itk-dependent signals required for CD4⁺ T cells to exert, but not gain, Th2 effector function. *J Immunol* 176:3895–3899
- Bacchetta R, Lucarelli B, Sartirana C, Gregori S, Lupo Stanghellini MT, Miquieu P, Tomiuk S, Hernandez-Fuentes M, Gianolini ME, Greco R et al (2014) Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. *Front Immunol* 5:16
- Bennett CL, Brunkow ME, Ramsdell F, O'Briant KC, Zhu Q, Fuleihan RL, Shigeoka AO, Ochs HD, Chance PF (2001) A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA-->AAUGAA) leads to the IPEX syndrome. *Immunogenetics* 53:435–439
- Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL (2005) Tec family kinases in T lymphocyte development and function. *Annu Rev Immunol* 23:549–600
- Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. *Clin Cancer Res* 14:3706–3715
- Bishop AC, Shah K, Liu Y, Witucki L, Kung C, Shokat KM (1998) Design of allele-specific inhibitors to probe protein kinase signaling. *Curr Biol* 8:257–266
- Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD et al (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase. *Nature* 407:395–401
- Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J (1998) T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. *J Immunol* 161:897–908
- Bohm L, Maxeiner J, Meyer-Martin H, Reuter S, Finotto S, Klein M, Schild H, Schmitt E, Bopp T, Taube C (2015) IL-10 and regulatory T cells cooperate in allergen-specific immunotherapy to ameliorate allergic asthma. *J Immunol* 194:887–897
- Brady MT, MacDonald AJ, Rowan AG, Mills KH (2003) Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. *Eur J Immunol* 33:3448–3457
- Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurf1, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet* 27:68–73
- Bunnell SC, Diehn M, Yaffe MB, Findell PR, Cantley LC, Berg LJ (2000) Biochemical interactions integrating Itk with the T cell receptor-initiated signaling cascade. *J Biol Chem* 275:2219–2230
- Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. *J Clin Invest* 106:R75–R81
- Clemente-Casares X, Blanco J, Ambalavanan P, Yamanouchi J, Singha S, Fandos C, Tsai S, Wang J, Garabatos N, Izquierdo C et al (2016) Expanding antigen-specific regulatory networks to treat autoimmunity. *Nature* 530:434–440
- Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, Belz GT, Smyth GK, Busslinger M, Nutt SL, Kallies A (2011) The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. *Nat Immunol* 12:304–311
- Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y, Nachury M, Brun V, Bastian H, Belmonte N et al (2012) Safety and efficacy of antigen-specific regulatory T-cell therapy for

- patients with refractory Crohn's disease. *Gastroenterology* 143(1207–1217):e1202
- Dombroski D, Houghtling RA, Labno CM, Precht P, Takesono A, Caplen NJ, Billadeau DD, Wange RL, Burkhardt JK, Schwartzberg PL (2005) Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton. *J Immunol* 174:1385–1392
- Felices M, Falk M, Kosaka Y, Berg LJ (2007) Tec kinases in T cell and mast cell signaling. *Adv Immunol* 93:145–184
- Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, Saris CJ, Gran B, Ciric B, Rostami A (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. *Nat Immunol* 8:1372–1379
- Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells. *Nat Immunol* 4:330–336
- Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, Locksley RM (1999) Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4⁺ T cells. *Immunity* 11:399–409
- Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F et al (2013) Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. *Nat Med* 19:739–746
- Gagliani N, Amezcuca Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limon P, Paiva RS, Ching T et al (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. *Nature* 523:221–225
- Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. *Curr Opin Rheumatol* 15:430–435
- Gilfillan AM, Rivera J (2009) The tyrosine kinase network regulating mast cell activation. *Immunol Rev* 228:149–169
- Gol-Ara M, Jadidi-Niaragh F, Sadria R, Azizi G, Mirshafiey A (2012) The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis. *Arthritis* 2012:805875
- Gomez-Rodriguez J, Sahu N, Handon R, Davidson TS, Anderson SM, Kirby MR, August A, Schwartzberg PL (2009) Differential expression of interleukin-17A and -17F is coupled to T cell receptor signaling via inducible T cell kinase. *Immunity* 31:587–597
- Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, Kirby MR, Belkaid Y, Schwartzberg PL (2014) Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. *J Exp Med* 211:529–543
- Gomez-Rodriguez J, Meylan F, Handon R, Hayes ET, Anderson SM, Kirby MR, Siegel RM, Schwartzberg PL (2016) Itk is required for Th9 differentiation via TCR-mediated induction of IL-2 and IRF4. *Nat Commun* 7:10857
- Grasis JA, Browne CD, Tsoukas CD (2003) Inducible T cell tyrosine kinase regulates actin-dependent cytoskeletal events induced by the T cell antigen receptor. *J Immunol* 170:3971–3976
- Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature* 389:737–742
- Hao S, Qi Q, Hu J, August A (2006) A kinase independent function for Tec kinase ITK in regulating antigen receptor induced serum response factor activation. *FEBS Lett* 580:2691–2697
- Haringer B, Lozza L, Steckel B, Geginat J (2009) Identification and characterization of IL-10/IFN- γ -producing effector-like T cells with regulatory function in human blood. *J Exp Med* 206:1009–1017
- Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. *Science* 299:1057–1061
- Huang W, Jeong AR, Kannan AK, Huang L, August A (2014) IL-2-inducible T cell kinase tunes T regulatory cell development and is required for suppressive function. *J Immunol* 193:2267–2272
- Huang W, Solouki S, Koylass N, Zheng SG, August A (2017) ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells. *Nat Commun* 8:15871
- Huber S, Gagliani N, Esplugues E, O'Connor W Jr, Huber FJ, Chaudhry A, Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY et al (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4⁺ T cells in an interleukin-10-dependent manner. *Immunity* 34:554–565
- Kannan A, Huang W, Huang F, August A (2012) Signal transduction via the T cell antigen receptor in naive and effector/memory T cells. *Int J Biochem Cell Biol* 44:2129–2134
- Kannan AK, Sahu N, Mohanan S, Mohinta S, August A (2013) IL-2-inducible T-cell kinase modulates TH2-mediated allergic airway inflammation by suppressing IFN- γ in naive CD4⁺ T cells. *J Allergy Clin Immunol* 132(811–820):e811–e815
- Kannan A, Lee Y, Qi Q, Huang W, Jeong AR, Ohnigian S, August A (2015) Allele-sensitive mutant, Itkas, reveals that Itk kinase activity is required for Th1, Th2, Th17, and iNKT-cell cytokine production. *Eur J Immunol* 45:2276–2285
- Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4⁺CD25⁺ T regulatory cells. *Nat Immunol* 4:337–342
- MacDonald AJ, Duffy M, Brady MT, McKiernan S, Hall W, Hegarty J, Curry M, Mills KH (2002) CD4 T helper type 1 and regulatory T cells induced against the

- same epitopes on the core protein in hepatitis C virus-infected persons. *J Infect Dis* 185:720–727
- Magnani CF, Alberigo G, Bacchetta R, Serafini G, Andreani M, Roncarolo MG, Gregori S (2011) Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. *Eur J Immunol* 41:1652–1662
- Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM et al (2015) Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-alpha. *Nat Med* 21:638–646
- McGuirk P, McCann C, Mills KH (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by *Bordetella pertussis*. *J Exp Med* 195:221–231
- Mfarrej B, Tresoldi E, Stabilini A, Paganelli A, Caldara R, Secchi A, Battaglia M (2017) Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression. *J Transl Med* 15:40
- Miller AT, Wilcox HM, Lai Z, Berg LJ (2004) Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet. *Immunity* 21:67–80
- Mobs C, Slotsch C, Löffler H, Jakob T, Hertl M, Pflutzer W (2010) Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. *J Immunol* 184:2194–2203
- Ndure J, Flanagan KL (2014) Targeting regulatory T cells to improve vaccine immunogenicity in early life. *Front Microbiol* 5:477
- Okamura T, Fujio K, Sumitomo S, Yamamoto K (2012) Roles of LAG3 and EGR2 in regulatory T cells. *Ann Rheum Dis* 71(Suppl 2):i96–i100
- Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak WG, Grunhagen D, Pan Q, Janssen H et al (2015) Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. *Onco Targets Ther* 4:e1008355
- Pellerin L, Jenks JA, Chinthrajah S, Dominguez T, Block W, Zhou X, Noshirvan A, Gregori S, Roncarolo MG, Nadeau KC, Bacchetta R (2018) Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. *J Allergy Clin Immunol* 141(202–213):e208
- Pot C, Apetoh L, Awasthi A, Kuchroo VK (2011) Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. *Semin Immunol* 23:438–445
- Qi Q, Xia M, Bai Y, Yu S, Cantorna M, August A (2011) Interleukin-2-inducible T cell kinase (Itk) network edge dependence for the maturation of iNKT cell. *J Biol Chem* 286:138–146
- Roncarolo MG, Gregori S, Bacchetta R, Battaglia M (2014) Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. *Curr Top Microbiol Immunol* 380:39–68
- Sahu N, Mueller C, Fischer A, August A (2008) Differential sensitivity to Itk kinase signals for T helper 2 cytokine production and chemokine-mediated migration. *J Immunol* 180:3833–3838
- Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol* 155:1151–1164
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. *Cell* 133:775–787
- Schaeffer EM, Debnath J, Yap G, McVicar D, Liao XC, Littman DR, Sher A, Varmus HE, Lenardo MJ, Schwartzberg PL (1999) Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. *Science* 284:638–641
- Schaeffer EM, Broussard C, Debnath J, Anderson S, McVicar DW, Schwartzberg PL (2000) Tec family kinases modulate thresholds for thymocyte development and selection. *J Exp Med* 192:987–1000
- Schaeffer EM, Yap GS, Lewis CM, Czar MJ, McVicar DW, Cheever AW, Sher A, Schwartzberg PL (2001) Mutation of Tec family kinases alters T helper cell differentiation. *Nat Immunol* 2:1183–1188
- Serafini G, Andreani M, Testi M, Battarra M, Bontadini A, Biral E, Fleischhauer K, Markt S, Lucarelli G, Roncarolo MG, Bacchetta R (2009) Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. *Haematologica* 94:1415–1426
- Shevach EM, McHugh RS, Piccirillo CA, Thornton AM (2001) Control of T-cell activation by CD4+ CD25+ suppressor T cells. *Immunol Rev* 182:58–67
- Shokat K, Velleca M (2002) Novel chemical genetic approaches to the discovery of signal transduction inhibitors. *Drug Discov Today* 7:872–879
- Smith-Garvin JE, Koretzky GA, Jordan MS (2009) T cell activation. *Annu Rev Immunol* 27:591–619
- Stumhofer JS, Silver JS, Laurence A, Porrett PM, Harris TH, Turka LA, Ernst M, Saris CJ, O'Shea JJ, Hunter CA (2007) Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. *Nat Immunol* 8:1363–1371
- Su YW, Zhang Y, Schweikert J, Koretzky GA, Reth M, Wienands J (1999) Interaction of SLP adaptors with the SH2 domain of Tec family kinases. *Eur J Immunol* 29:3702–3711
- Takesono A, Finkelstein LD, Schwartzberg PL (2002) Beyond calcium: new signaling pathways for Tec family kinases. *J Cell Sci* 115:3039–3048

- Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou AI, Brodie TM, Poulos N, Samitas K, Kapasa M, Konstantopoulos D et al (2017) Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. *Proc Natl Acad Sci U S A* 114:E2891–E2900
- Vignali DA, Collison LW, Workman CJ (2008) How regulatory T cells work. *Nat Rev Immunol* 8:523–532
- Volz T, Skabytska Y, Guenova E, Chen KM, Frick JS, Kirschning CJ, Kaesler S, Rocken M, Biedermann T (2014) Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. *J Invest Dermatol* 134:96–104
- Werlen G, Palmer E (2002) The T-cell receptor signalosome: a dynamic structure with expanding complexity. *Curr Opin Immunol* 14:299–305
- Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L et al (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet* 27:18–20
- Zeng H, Zhang R, Jin B, Chen L (2015) Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance. *Cell Mol Immunol* 12:566–571